Drug Profile
SYGN 309
Alternative Names: SYGN-309Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Synedgen
- Class Polysaccharides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal disorders
Most Recent Events
- 12 Sep 2023 SYGN 309 is still in preclinical development for Gastrointestinal disorders in USA (PO) (Synedgen pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA (PO)
- 28 Jul 2016 Preclinical trials in Gastrointestinal disorders in USA (PO)